Ocean Biomedical Inc.

Ocean Biomedical Inc. a biopharmaceutical company focuses on discovering and developing therapeutic products in oncology fibrosis and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1 and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP. The company is based in Providence Rhode Island. Ocean Biomedical Inc. operates as a subsidiary of Poseidon Bio LLC.